Contrast agent developer Epix Medical reported first-quarter revenues of $3.5 million, compared to $2.1 million in the first quarter of 2002. For the period (end-March 31), the Cambridge, MA-based firm had a net loss of $5.4 million, compared with a net loss of $4.6 million reported in the first quarter of 2002. The firm attributed the increase in sales to growth in product development revenues from Schering.
By AuntMinnie.com staff writersApril 25, 2003
Related Reading
Epix to develop new MR agent, April 1, 2003
Epix contrast agent clears second phase III trial, March 8, 2003
Epix testing of MS-325 moves forward, February 4, 2003
Epix losses continue, MS-325 enrollment completed, October 25, 2002
Epix net loss widens, delays MS-325 NDA, July 26, 2002
Copyright © 2003 AuntMinnie.com
